These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 38004071

  • 1. Cutaneous Toll-like Receptor 9 Pre-Defines Hydroxychloroquine Dosage in Patients with Both Discoid and Subacute Lupus Erythematosus.
    Englert KA, Dyduch G, Kłosowicz A, Spałkowska M, Jaworek AK, Migacz-Gruszka K, Jarosz-Chudek A, Mercuri SR, Szpor J, Mazzoccoli G, Damiani G, Wojas-Pelc A.
    Medicina (Kaunas); 2023 Nov 17; 59(11):. PubMed ID: 38004071
    [Abstract] [Full Text] [Related]

  • 2. Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus.
    Gardet A, Pellerin A, McCarl CA, Diwanji R, Wang W, Donaldson D, Franchimont N, Werth VP, Rabah D.
    Front Immunol; 2019 Nov 17; 10():275. PubMed ID: 30846987
    [Abstract] [Full Text] [Related]

  • 3. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study.
    Ikeda T, Kanazawa N, Furukawa F.
    J Dermatol; 2012 Jun 17; 39(6):531-5. PubMed ID: 22168306
    [Abstract] [Full Text] [Related]

  • 4. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
    Morita S, Takahashi T, Yoshida Y, Yokota N.
    Ther Drug Monit; 2016 Apr 17; 38(2):259-67. PubMed ID: 26587870
    [Abstract] [Full Text] [Related]

  • 5. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F, Arnaud L, Costedoat-Chalumeau N, Zahr N, Bessis D, Francès C.
    J Am Acad Dermatol; 2016 Apr 17; 74(4):693-9.e3. PubMed ID: 26850655
    [Abstract] [Full Text] [Related]

  • 6. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
    Momose Y, Arai S, Eto H, Kishimoto M, Okada M.
    J Dermatol; 2013 Feb 17; 40(2):94-7. PubMed ID: 23216212
    [Abstract] [Full Text] [Related]

  • 7. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N, Tanikawa A, Amagai M, Kato Y, Momose Y, Arai S, Eto H, Ikeda T, Furukawa F.
    Mod Rheumatol; 2013 Mar 17; 23(2):318-22. PubMed ID: 22581095
    [Abstract] [Full Text] [Related]

  • 8. Clinicohistological and immunopathological features of patients with cutaneous lupus erythematosus at tertiary dermatology centre in Malaysia.
    Teh YC, Loo CH, Mohd Ali N, Lim AL, Tan WC.
    Clin Exp Dermatol; 2022 Aug 17; 47(8):1490-1501. PubMed ID: 35315538
    [Abstract] [Full Text] [Related]

  • 9. Skin CD4+ Trm cells distinguish acute cutaneous lupus erythematosus from localized discoid lupus erythematosus/subacute cutaneous lupus erythematosus and other skin diseases.
    Zhao Z, Zhu H, Li Q, Liao W, Chen K, Yang M, Long D, He Z, Zhao M, Wu H, Lu Q.
    J Autoimmun; 2022 Apr 17; 128():102811. PubMed ID: 35278775
    [Abstract] [Full Text] [Related]

  • 10. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
    Zeidi M, Chen KL, Patel J, Desai K, Kim HJ, Chakka S, Lim R, Werth VP.
    Lupus; 2022 Apr 17; 31(4):472-481. PubMed ID: 35258358
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
    Yokogawa N, Eto H, Tanikawa A, Ikeda T, Yamamoto K, Takahashi T, Mizukami H, Sato T, Yokota N, Furukawa F.
    Arthritis Rheumatol; 2017 Apr 17; 69(4):791-799. PubMed ID: 27992698
    [Abstract] [Full Text] [Related]

  • 13. Correlation of whole blood hydroxychloroquine concentration with cutaneous lupus erythematosus and factors associated with it: First multicenter, cross-sectional analysis in Malaysia.
    Peh D, Wan Ahmad Kammal WSL, Beh PJ, Yong ACH, Tan WC, Lim AL, Thevarajah S, Stanslas J, How KN.
    J Dermatol; 2022 May 17; 49(5):545-549. PubMed ID: 35067938
    [Abstract] [Full Text] [Related]

  • 14. Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
    Zeidi M, Kim HJ, Werth VP.
    J Invest Dermatol; 2019 Feb 17; 139(2):324-332. PubMed ID: 30227141
    [Abstract] [Full Text] [Related]

  • 15. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
    Carter LM, Wigston Z, Laws P, Vital EM.
    Br J Dermatol; 2023 Jul 17; 189(2):210-218. PubMed ID: 36944572
    [Abstract] [Full Text] [Related]

  • 16. Apoptosis of keratinocytes and serum DNase I activity in patients with cutaneous lupus erythematosus: relationship with clinical and immunoserological parameters.
    Skiljevic D, Bonaci-Nikolic B, Brasanac D, Nikolic M.
    J Eur Acad Dermatol Venereol; 2017 Mar 17; 31(3):523-529. PubMed ID: 27557471
    [Abstract] [Full Text] [Related]

  • 17. The effect of hydroxychloroquine on lupus erythematosus-like skin lesions in MRL/lpr mice.
    Shimomatsu T, Kanazawa N, Mikita N, Nakatani Y, Li HJ, Inaba Y, Ikeda T, Kondo T, Furukawa F.
    Mod Rheumatol; 2016 Sep 17; 26(5):744-8. PubMed ID: 26873035
    [Abstract] [Full Text] [Related]

  • 18. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score.
    Braunstein I, Klein R, Okawa J, Werth VP.
    Br J Dermatol; 2012 May 17; 166(5):971-5. PubMed ID: 22242767
    [Abstract] [Full Text] [Related]

  • 19. Clinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus.
    David-Bajar KM, Bennion SD, DeSpain JD, Golitz LE, Lee LA.
    J Invest Dermatol; 1992 Sep 17; 99(3):251-7. PubMed ID: 1512459
    [Abstract] [Full Text] [Related]

  • 20. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A, Porta S, Ríos R, Martinez-Zapico A, Ortego-Centeno N, Agesta N, Ruiz-Irastorza G.
    Lupus; 2018 Sep 17; 27(10):1718-1722. PubMed ID: 29635998
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.